Are any peptide products legally available in Australia?

Some peptides are registered therapeutic goods approved by the TGA for specific medical uses — for example, synthetic hormone analogues used in fertility treatment or cancer care. However, the peptides widely promoted online for anti-ageing, muscle recovery, weight loss, or healing — such as BPC-157, TB-500, Melanotan, Ipamorelin, and CJC-1295 — are not listed on the Australian Register of Therapeutic Goods for human use. Supplying, advertising, or importing them for personal use without authorisation is unlawful. Compounding pharmacies cannot legally produce peptides that are not approved therapeutic goods. To check whether a specific product is registered, search the ARTG at tga.gov.au.

Why are influencers still promoting peptides if they are illegal?

Unlawful advertising of therapeutic goods is one of the TGA's stated compliance targets in 2026. Social media platforms are not regulated in the same way as broadcasters, and enforcement against individual influencers is slower than product seizures. The TGA's shift to make peptides a formal compliance priority means more resources go to detection and prosecution. GPs have also been explicitly asked to engage with patients who come in with questions about peptide use — and to help redirect that conversation toward evidence.

TGA makes unapproved peptides a compliance priority — what to know

What just happened

The Therapeutic Goods Administration formally escalated unapproved peptide products as a compliance priority for 2026 on 10 June, in what the regulator describes as a “scaling up of regulatory attention” following increased detection of unlawful importation, supply, and advertising. TGA head Professor Anthony Lawler stated that growing availability of unregulated peptides has brought increasing evidence of consumer risk.

The announcement lands in a particular moment. If you move in health-conscious circles — or follow fitness and longevity accounts — you have almost certainly encountered peptide claims. BPC-157 promoted for gut healing and tendon repair. TB-500 for injury recovery. Melanotan for tanning. Ipamorelin and CJC-1295 for growth hormone release. The claims travel fast. The evidence does not travel with them, and neither does the regulatory status — which, under Australian law, is unambiguous.

The person reading this might have tried one of these products, or is thinking about it, or is watching someone in her life promote them. The TGA’s escalation is not background noise. It is worth understanding clearly, because the risks here are real and they are not disclosed on the packaging.

The both-and

The enthusiasm for peptides reflects something real about the limits of conventional medicine in the wellness space. The regulatory and safety picture is more complicated than the influencer content suggests.

What the evidence actually shows

Peptides are short chains of amino acids. Some have legitimate, well-characterised therapeutic roles — synthetic hormone analogues used in fertility treatment, for example, or growth hormone-releasing peptides used in diagnosed growth disorders. These are TGA-approved, manufactured under quality standards, and dispensed through regulated channels.

The peptides circulating in the wellness economy are a different category. BPC-157, TB-500, Ipamorelin, CJC-1295, and Hexarelin have shown promise in cell studies and animal models. The problem — which is a persistent problem in this space — is that promising in-vitro and rodent data does not reliably translate to human clinical benefit. The human trial data is thin. The manufacturing standards of unlicensed suppliers are unknown. Dosing information circulating online is derived from research protocols, not therapeutic guidance.

Reported safety risks from unapproved peptide use include severe allergic reactions, inflammation, palpitations, insomnia, blurred vision, and musculoskeletal injuries. Contamination is a specific concern: products ordered online and injected without medical supervision carry unknown sterility profiles.

Melanotan II sits in a particularly stark regulatory position: Schedule 9 in Australia — the same schedule as MDMA and heroin — because of its documented risk profile, which includes melanoma signalling concerns, priapism, and cardiovascular effects. It remains widely available online despite this.

The supply chain being targeted

The April 2026 joint operation with the Australian Border Force and Victoria Police resulted in seizures of more than $2 million in illicit steroids and peptides, with three Victorians arrested. May 2026 brought Operation Pangea XVIII — a coordinated global enforcement action — in which more than 900,000 unlawfully imported therapeutic goods were seized in Australia alone. These are not small-scale operations. The supply chain is substantial, and it is not operating in a legal grey area. It is operating in a clearly illegal space.

The June 10 announcement formalises unapproved peptides as a TGA compliance priority for 2026, meaning dedicated resourcing for consumer education, import monitoring, product seizures, and enforcement — including infringement notices, civil penalties, and where warranted, criminal prosecution. Penalties extend to suppliers, advertisers, and importers.

It is worth noting that the June 4 TGA safety alert on MK-677 (ibutamoren) capsules was part of the same enforcement pattern — but the June 10 compliance escalation is broader, covering the entire category of unapproved peptide products rather than a single product line.

The framing problem in the wellness ecosystem

The wellness sector applies a consistent framing to regulatory action: cast it as institutional conservatism suppressing innovation. Regulators always lag behind the science. The evidence is there — they just won’t approve it.

The problem with applying that frame here is that the TGA’s approval pathway is available to any sponsor who demonstrates safety, quality, and efficacy. Peptide manufacturers have not pursued that pathway. The regulatory absence is not because the TGA has blocked approval — it is because no sponsor has met the evidentiary standard for approval for the indications being promoted online.

That is a meaningful distinction. Biologically active is not the same as safe and effective at the dose you are using, made in the facility that produced yours.

2 cents

If you are currently using peptide products sourced online, or considering them: talk to your GP before continuing. Not because the evidence is conclusively against all peptides — it is not. But because the product you have is of unknown quality, the dose is unverified, and the risk-benefit calculation cannot be made without knowing those things.

If you have been told by an online clinic that they can prescribe peptides legally: that warrants scrutiny. Compounding pharmacies in Australia cannot legally produce peptides that are not approved therapeutic goods, regardless of the order form.

This is general health information and does not constitute individual clinical advice.

Verdict

Verdict: yes — worth knowing about.

The TGA’s formal compliance escalation on unapproved peptides is clinically significant because of the patient safety risks documented, the scale of the unlawful supply chain, and the direct relevance to the GP consultation — where patients increasingly arrive with questions shaped by influencer content rather than evidence. The answer to those questions is now clearly on the record.